Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma

Condition(s) targeted: Multiple Myeloma

Intervention: Comparator: vorinostat (an HDAC inhibitor) (Drug); Comparator: bortezomib (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: Merck

Official(s) and/or principal investigator(s):
Medical Monitor, Study Director, Affiliation: Merck

Overall contact:
Toll Free Number, Phone: 1-888-577-8839

Study of bortezomib administered in combination with vorinostat or placebo in patients with relapsed or refractory multiple myeloma.

Histone deacetylases (HDAC) facilitate gene transcription by modulating the uncoiling of chromatin. HDAC function is dysregulated in hematologic and solid malignancies, and this dysregulation may result in over-expression of oncogenes. Thus, inhibition of HDACs may result in anti-cancer effects. HDAC inhibitors, like vorinostat, represent a new class of antitumor agents that have the ability to induce antiproliferative effects including cyto-differentiation, cell cycle growth arrest or apoptosis in various cancer cell lines. Several studies have investigated the in vitro antimyeloma activity of vorinostat in combination with bortezomib and have demonstrated that vorinostat may act synergistically with bortezomib to modulate tumor cell growth. Mitsiades et al have shown that vorinostat enhances the sensitivity of bortezomib. Pei et al found that exposure of human multiple myeloma cell lines & patient-derived multiple myeloma cells to bortezomib and vorinostat resulted in synergistic interactions as a result of: (1) Interruption of NF-kB & related signaling pathways (JNK, XIAP, Mcl-1, etc.) (2) Inhibition of Hsp90 (3) Induction of ER stress signal and (4) acetylation of Dynein/ disruption of aggresome function/formation, salvage for ubiquitinated proteins. In addition a marked increase in mitochondrial injury, caspase activation, and apoptosis was also observed.

Bortezomib is indicated for the treatment of patients with multiple myeloma. Two Phase I dose-ranging studies of a regimen combining vorinostat and bortezomib among patients with relapsed as well as end-stage, refractory multiple myeloma have been conducted. These studies enrolled a total of 57 patients. In these studies, administration of vorinostat with standard doses of bortezomib resulted in responses in 20/45 (44%) evaluable patients (Weber et al 2007, Badros et al 2007). The purpose of the present study is to definitively evaluate the clinical activity of vorinostat in combination with bortezomib in patients with multiple myeloma

Official title: An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma

Study design: Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Single Group Assignment, Efficacy Study

Primary outcome: Determine the PFS (progression free survival) in patients with multiple myeloma, treated with bortezomib and vorinostat compared to patients treated with bortezomib and placebo

Secondary outcome: Assess the tolerability of vorinostat administered in combination with bortezomib.

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

Patient is 18 years of age or older

- Patient has an established diagnosis of multiple myeloma based on the myeloma

diagnostic criteria

- Patient has received at least 1 but not more than 3 prior anti-myeloma regimens and

has progressive disease after the most recent treatment regimen

- Patient must have adequate organ function

Exclusion Criteria:

- Patient has had a prior allogeneic bone marrow transplant or plans to undergo any

type of bone marrow transplantation within 4 weeks of the initiation of study therapy

- Patient has known hypersensitivity to any components of bortezomib or vorinostat

- Patient has active Hepatitis B or C, plasma cell leukemia, or is HIV positive

- Patient has had prior treatment with vorinostat or HDAC inhibitors

Toll Free Number, Phone: 1-888-577-8839

Merck Sharp & Dohme (Australia) Pty Ltd., South Granville NSW 2142, Australia; Recruiting
David Woolner, Phone: 64-9-523-6075

Merck Sharp & Dohme B.V., Bruxelles 1180, Belgium; Recruiting
Nathalie Schrameijer, Phone: 32-2-373-4310

Merck Sharp & Dohme IDEA Inc., Sofia, Bulgaria; Recruiting
Aneta Sokolova, Phone: 359-2-963-1076

Merck Sharp & Dohme IDEA Inc., Praha 162 00, Czech Republic; Recruiting
Simona Martinkova, Phone: 420-233-010-213

Msd Sharp & Dohme Gmbh, Haar 85540, Germany; Recruiting
Thomas Lang, Phone: 49-89-4561-1536

Vianex, S.A. / MSD, Nea Erythrea 146 71, Greece; Recruiting
Fotini Vlasserou, Phone: 30-210-8009435

MSD Magyarorszag Kft., Budapest 1123, Hungary; Recruiting
Geza Szoverffy, Phone: 36-1 888 5325

MSD Pharmaceuticals Private Ltd., New Delhi 110011, India; Recruiting
Swashraya Shah, Phone: 91-124-464-7338

Merck Sharp & Dohme (Italia) S.P.A., Roma 191, Italy; Recruiting
Gianfranco Botta, Phone: 39 06 36 191187

MSD Korea Ltd., Seoul 121-705, Korea, Republic of; Recruiting
Steve Kim, Phone: 82-2-6363-0241

Merck Sharp & Dohme (I.A.) Corp, Selangor 46300, Malaysia; Recruiting
Nazrin Azli, Phone: 603-77181748

Merck Sharp & Dohme (New Zealand) Ltd.,, Auckland, New Zealand; Recruiting
David Woolner, Phone: 64-9523-6075

MSD Polska Sp. z o.o. Dzial Medyczny, Warszawa 00-867, Poland; Recruiting
Adam Czernik, Phone: 48 22 549-51-39

Merck Sharp & Dohme Lda, Paco D`arcos 2770-192, Portugal; Recruiting
Lai Hung Jen, Phone: 351-21-4465821

Merck Sharp & Dohme IDEA, Inc., Moscow 121059, Russian Federation; Recruiting
Tatiana Serebriakova, Phone: 7-495-941-8264

Merck Sharp & Dohme De Espana, S.A.E., Madrid 28027, Spain; Recruiting
Jorge Gonzalez-Esteban, Phone: 34-91-3210-728

Merck Sharp & Dohme (I.A.) Corp., Taipei 106, Taiwan; Recruiting
David Chung, Phone: 886-2-23761670

Call for Information, Tucson, Arizona 85715, United States; Recruiting

Call for Information, Anaheim, California 92801, United States; Recruiting

Call for Information, Los Angeles, California 90095, United States; Recruiting

Call for Information, Palm Springs, California 92262, United States; Recruiting

Merck Sharp & Dohme De Mexico, S.A. De C.V., Mexico, D.F. 1090, Mexico; Recruiting
Juan Diaz, Phone: 52-55-5481-9825

MSD (Pty) LTD South Africa, Midrand, Gauteng 1685, South Africa; Recruiting
Beverley Cowper, Phone: 27 11 655-3036

Call for Information, Atlanta, Georgia 30322, United States; Recruiting

Call for Information, Savannah, Georgia 31405, United States; Recruiting

Merch Sharp & Dohme Ltd., Hoddesdon, Hertfordshire EN11 9BU, United Kingdom; Recruiting
Paul Robinson, Phone: 44 1992 452341

Call for Information, Centralia, Illinois 62801, United States; Recruiting

Call for Information, Chicago, Illinois 60612, United States; Recruiting

Call for Information, Indianapolis, Indiana 46254, United States; Recruiting

Call for Information, Boston, Massachusetts 02115-6084, United States; Recruiting

Call for Information, Boston, Massachusetts 02115, United States; Recruiting

Call for Information, Duluth, Minnesota 55805, United States; Recruiting

Call for Information, Jefferson City, Missouri 65109-0000, United States; Recruiting

Call for Information, Hackensack, New Jersey 07601, United States; Recruiting

Call for Information, Albuquerque, New Mexico 87131, United States; Recruiting

Call for Information, New York, New York 10011, United States; Recruiting

Call for Information, New York, New York 10021, United States; Recruiting

Call for Information, Canton, Ohio 44718, United States; Recruiting

Call for Information, Ephrata, Pennsylvania 17522, United States; Recruiting

Merck Frosst Canada Ltd., Kirkland, Quebec H9H 3L1, Canada; Recruiting
Michel Cimon, Phone: 514-428-2605

Call for Information, Charleston, South Carolina 29425, United States; Recruiting

Call for Information, Mt. Pleasant, South Carolina 29464, United States; Recruiting

Call for Information, Sumter, South Carolina 29150, United States; Recruiting

Call for Information, Corpus Christi, Texas 78404, United States; Recruiting

Call for Information, Dallas, Texas 75390, United States; Recruiting

Call for Information, Salt Lake City, Utah 84106, United States; Recruiting

Starting date: October 2008
Ending date: October 2011
Last updated: October 16, 2009